A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that ...

可切除 ATC 可行手术切除后辅助放化疗。而不可切除 ATC 治疗选择有限。ATC 最常见的驱动基因是 BRAF 突变，占全部 ATC 的 40% [4] 。2018 年，美国食品药品监督管理局（FDA）批准达拉非尼和曲美替尼 ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

撰写这篇国际专家共识的初衷源于一次肺癌会议上的深刻讨论，我们意识到尽管BRAF突变在多种肿瘤中普遍存在，但其检测与治疗策略却缺乏统一的标准，导致患者治疗效果参差不齐。会议中，一位年轻的肺腺癌患者，由于早期未能准确检测到BRAF ...

It also covers Novartis’ Mekinist (trametinib) in melanoma as well as other BRAF inhibitors and BRAF/MEK combination ...

In August 2024, Elicio received a $1.5M grant from the Gastro-Intestinal Research Foundation to support continued development of vaccines targeting p53 and BRAF mutations. In July 2024, a $11.5M ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

75-year-old patient with BRAF mutant metastatic cutaneous melanoma who had previously received pembrolizumab followed by dabrafenib plus trametinib. Following treatment with NUC-3373 plus ...

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...